Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04691505 · ClinicalTrials.gov registry record
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Methotrexate vs Hydroxychloroquine
A clinical trial of Rheumatoid Arthritis, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 133,553
- Enrollment target
- 1
- Study location
NCT04691505: Completed study of Rheumatoid Arthritis, sponsored by Brigham and Women's Hospital.
NCT04691505 is a study of Rheumatoid Arthritis that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 133,553 participants, above the 4,013-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (3228% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04691505, a study of Rheumatoid Arthritis, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 133,553 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Primary Outcome
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.
Conditions Studied
Interventions
- DRUG Methotrexate
- DRUG Hydroxychloroquine
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133,553 participants |
| Start Date | 2020-12-23 |
| Est. Completion | 2021-08-31 |
What the finished NCT04691505 record still lists
NCT04691505 is an observational study that tracks outcomes without assigning an intervention. Its 133,553 participants enrollment target places it among the larger protocols in the corpus, above the 4,013-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (3228% higher).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Methotrexate is the first listed.
NCT04691505 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04691505 about?
NCT04691505 is a clinical study titled "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Methotrexate vs Hydroxychloroquine". This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
What is the current status of trial NCT04691505?
This trial is currently completed. The enrollment target is 133,553 participants. The study started on 2020-12-23. Estimated completion is 2021-08-31.
What conditions does trial NCT04691505 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT04691505?
The interventions under investigation include: Methotrexate (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT04691505?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04691505 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04691505's enrollment target sits among peer trials
133,553 2nd of 197 the highest of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rheumatology Diet Study
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
RECRUITING · NA
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Physica System Total Knee Replacement Registry Study
RECRUITING · NA
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05994482 · 130,000 participants
Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study
- NCT02693509 · 128,026 participants
Get With The Guidelines-Heart Failure Registry
- NCT03897374 · 120,000 participants
Strategic Targeting for Optimal Prevention of Cancer
- NCT06608758 · 120,000 participants
End Diagnostic Overshadowing:Addressing Ableism in Diagnoses
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI